An interventional study of Dexamthsone and Bupivacaine in Duration of Pain Relief, sponsored by University of Chicago. Terminated at 1 site in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2019-05-14.
Sponsored by University of Chicago · Not applicable, Interventional, and Treatment
Effect of dexamethasone on prolonging upper extremity block is well known. But it not known if the effect comes from its local effect on the nerves or from its general analgesic effect. In this study we will compare the systemic effect to its local effect to find out if there is a difference or not.
University of Chicago is the lead sponsor of 907 studies on the registry; 182 are open to participants now.
Of its 99 completed or terminated interventional studies of FDA-regulated products, 68 (69%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Control
Drug: Bupivacaine
Dexamethasone will be mixed with bupivacaine
Drug: Dexamthsone · Drug: Bupivacaine
Dexamethasone will be given intravenously
Drug: Dexamthsone · Drug: Bupivacaine
Analgesia Duration
Time frame: 72 hrs
| Milestone | Bupivacaine | Bupivacaine With Dexamethasone | Intravenous Dexamethasone |
|---|---|---|---|
| Started | 3 | 1 | 1 |
| Completed | 3 | 1 | 1 |
| Not completed | 0 | 0 | 0 |
No measurements were reported for this outcome.
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Bupivacaine | — | 0/3 (0%) | 0/3 (0%) |
| Bupivacaine With Dexamethasone | — | 0/1 (0%) | 0/1 (0%) |
| Intravenous Dexamethasone | — | 0/1 (0%) | 0/1 (0%) |
| Age, Categorical(Participants) | Bupivacaine | Bupivacaine With Dexamethasone | Intravenous Dexamethasone | Total |
|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 3 | 1 | 1 | 5 |
| >=65 years | 0 | 0 | 0 | 0 |
| Sex/Gender, Customized(Participants) | Bupivacaine | Bupivacaine With Dexamethasone | Intravenous Dexamethasone | Total |
|---|---|---|---|---|
| Female | 2 | 1 | 1 | 4 |
| Male | 1 | 0 | 0 | 1 |
| Region of Enrollment(Participants) | Bupivacaine | Bupivacaine With Dexamethasone | Intravenous Dexamethasone | Total |
|---|---|---|---|---|
| United States | 3 | 1 | 1 | 5 |
This study is terminated, as verified in Apr 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Chicago